Literature DB >> 26623133

Epithelioid inflammatory myofibroblastic sarcoma: a case report.

Daniel E Sarmiento1, Jessica A Clevenger1, Gregory A Masters1, Thomas L Bauer1, Brian T Nam1.   

Abstract

Inflammatory myofibroblastic tumor (IMT) of the lung is a rare malignancy with few cases reported in the literature. Histologically, it is composed by spindle cells and an infiltrate of inflammatory cells. Children and young, non-smoking adults constitute the majority of cases, the clinical behavior ranges from a benign entity to a malignant process with rapid recurrence and metastatic progression. We present a case of epithelioid inflammatory myofibroblastic sarcoma (EIMS) of the pleura, a malignant variant of IMT, which was initially treated with debulking surgical resection followed by systemic chemotherapy. The tumor was found to have an anaplastic lymphoma kinase (ALK) gene rearrangement. An ALK directed tyrosine kinase inhibitor was used with an impressive response, the patient remains in remission nearly 1 year after presentation. The pathogenesis, pathologic findings, clinical behavior and imaging of pulmonary EIMS are discussed.

Entities:  

Keywords:  Pleura; gene polymorphism; sarcoma

Year:  2015        PMID: 26623133      PMCID: PMC4635277          DOI: 10.3978/j.issn.2072-1439.2015.10.55

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  10 in total

1.  Inflammatory myofibroblastic tumor of the lung: a benign lesion with aggressive behavior.

Authors:  Sonia Ezzine-Baccari; Dhouha Bacha; Sélim Sassi; Maher Abouda; Hédia Ghrairi; Hassen Touinsi; Sadok Sassi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-06-06

2.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  ALK inhibition for the treatment of refractory epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Mikihiro Fujiya; Yutaka Kohgo
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

4.  Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity.

Authors:  Yoshiki Kozu; Mitsuhiro Isaka; Yasuhisa Ohde; Kengo Takeuchi; Takashi Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-01-24

Review 5.  Myofibroblastic malignancies.

Authors:  Cyril Fisher
Journal:  Adv Anat Pathol       Date:  2004-07       Impact factor: 3.875

6.  RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors.

Authors:  Ankita S Patel; Kathleen M Murphy; Anita L Hawkins; Julie S Cohen; Patricia P Long; Elizabeth J Perlman; Constance A Griffin
Journal:  Cancer Genet Cytogenet       Date:  2007-07-15

Review 7.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

8.  Invasive inflammatory myofibroblastic tumor of the lung.

Authors:  Daniel A van den Heuvel; Ruth G Keijsers; Hendrik W van Es; Gerben P Bootsma; Peter C de Bruin; Franz M Schramel; Johannes P van Heesewijk
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

Review 9.  Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.

Authors:  Jian Li; Wei-hua Yin; Kengo Takeuchi; Hong Guan; Yu-hua Huang; John K C Chan
Journal:  Diagn Pathol       Date:  2013-09-13       Impact factor: 2.644

10.  Inflammatory myofibroblastic tumor of the lung and the maxillary region: a benign lesion with aggressive behavior.

Authors:  Lorena Gallego; Tania R Santamarta; Verónica Blanco; Luis García-Consuegra; Tommaso Cutilli; Luis Junquera
Journal:  Case Rep Dent       Date:  2013-03-06
  10 in total
  7 in total

Review 1.  Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.

Authors:  Shefali Chopra; Nolan Maloney; Wei Lien Wang
Journal:  Brain Tumor Pathol       Date:  2021-11-06       Impact factor: 3.298

2.  Pericardial Epithelioid Inflammatory Myofibroblastic Sarcoma: An Atypical Presentation.

Authors:  Mazieyar Azad; Melissa Oye; Natalie Torrente; Mehdi Mirsaeidi
Journal:  Cureus       Date:  2022-07-13

3.  Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review.

Authors:  Priyanka Singh; Aruna Nambirajan; Manish Kumar Gaur; Rahul Raj; Sunil Kumar; Prabhat Singh Malik; Deepali Jain
Journal:  J Pathol Transl Med       Date:  2022-07-07

4.  Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Quan Jiang; Han-Xing Tong; Ying-Yong Hou; Yong Zhang; Jing-Lei Li; Yu-Hong Zhou; Jing Xu; Jiong-Yuan Wang; Wei-Qi Lu
Journal:  Orphanet J Rare Dis       Date:  2017-05-23       Impact factor: 4.123

5.  Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China.

Authors:  Wei Song; Yan Zhu
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

Review 6.  Inflammatory Myofibroblastic Tumour: State of the Art.

Authors:  Louis Gros; Angelo Paolo Dei Tos; Robin L Jones; Antonia Digklia
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

7.  Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.

Authors:  Charis Durham; Matthew Clemons; Alwin Alias; Kartik Konduri
Journal:  Cureus       Date:  2022-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.